FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to otorhinolaryngology, and may be used for treating and preventing a nasal obstruction in the patients with polypous rhinosinusitis. That is ensured by prescribing Singulair to be administered per os in a dose of 5 mg daily for 5 months with underlying topic corticosteroids.
EFFECT: method enables non-operative breath management the over a relatively short time ensured by reducing the polypous tissue volume with a lower drug-induced load.
2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF EVALUATING THE EFFICIENCY OF MEDICAMENTAL THERAPY OF ACUTE EXACERBATIONS OF CHRONIC PURULENT SINUSITIS | 2015 |
|
RU2600645C2 |
METHOD FOR TREATING CHRONIC POLYPOUS RHINOSINUSITIS | 2000 |
|
RU2163097C1 |
METHOD FOR EVALUATING EFFICACY OF DRUG-INDUCED THERAPY OF POLYPOUS RHINOSINUSITIS | 2010 |
|
RU2428695C1 |
METHOD OF POLYPOUS RHINOSINUSITIS TREATMENT | 2017 |
|
RU2646806C1 |
PREDICTION METHOD OF POLYPOUS RHINOSINUSITIS RELAPSE RISK FOR PREVENTIVE THERAPY INDICATIONS | 2007 |
|
RU2338205C1 |
MUCOLYTIC COLLECTION FOR THE TREATMENT OF RHINOSINUSITIS POLYPOSA | 2021 |
|
RU2762350C1 |
METHOD OF POLYPOUS RHINOSINUSITIS TREATMENT | 2006 |
|
RU2329059C1 |
METHOD OF TREATING POLYPOUS RHINOSINUSITIS | 2017 |
|
RU2646492C1 |
METHOD FOR TREATMENT OF OLFACTORY DYSFUNCTION IN PATIENTS WITH ACUTE RHINOSINUSITIS | 2017 |
|
RU2638688C1 |
METHOD OF TREATING PATIENTS WITH RHINOSINUSITIS | 2014 |
|
RU2580657C1 |
Authors
Dates
2013-11-27—Published
2012-02-07—Filed